Facebook Inc removed 16,000 groups for selling or buying fake reviews of products and services on its platforms, after a second prompt by UK’s competition watchdog CMA.
CMA Chief Executive Andrea Coscelli said that the pandemic has meant that more and more people are buying online, which makes fake and misleading reviews very damaging.
A representative of the social media giant said they have engaged extensively with the CMA to address this issue, emphasizing that they do not allow fraudulent and deceptive activity, including offering or trading fake reviews.
The CMA began a crackdown on false reviews in 2019 when it found evidence of a growing marketplace for misleading customer reviews on the platforms.
It then asked Facebook and e-commerce platform eBay Inc to check their websites.
Facebook has also been under scrutiny for antitrust concerns over the technology company’s acquisition of GIF website Giphy, as well as its data-sharing practices, fake news, and hate speech.


Universal Music Group Rejects Pershing Square Takeover Proposal
US Quantum Stocks Surge After $2 Billion Government Investment
Anthropic Files for IPO, Signaling a New Era for Public AI Investments in 2026
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence
HPE Raises 2026 Outlook After Record Q2 Revenue Fueled by AI Server Demand
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs
Nvidia Unveils RTX Spark AI PC Chips, Expands Challenge to Intel, AMD, and Apple
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028
LG Electronics Stock Hits Record High on Nvidia AI Partnership Speculation
Fonterra to End Fitch Ratings Coverage as Agency Plans Withdrawal
SoftBank to Invest €75 Billion in France AI Data Center Expansion by 2031
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027
Costco Q3 Fiscal 2026 Earnings Beat Expectations as Sales and E-Commerce Surge
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks




